---
schema_version: "secwatch.filing_event.v1"
accession: "0001682852-23-000025"
form_type: "8-K"
ticker: "MRNA"
cik: "0001682852"
company_name: "Moderna, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:40:02.852332+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moderna Q2 net loss $1.4B, EPS -$3.62; revenue $344M (-93% YoY); FY23 sales guidance $6-8B

## Summary
- Q2 revenue $344M vs $4.7B YoY; product sales $293M, down 94% due to lower COVID vaccine volume.
- Net loss $1.4B vs net income $2.2B YoY; diluted EPS -$3.62 vs +$5.24.
- Cost of sales $731M includes $464M inventory write-downs, $135M unutilized capacity, $75M purchase commitment losses.
- Guides FY23 COVID vaccine sales $6-8B; expects ~$1B of APAs deferred to 2024; cost of sales now $3.5-4B.
- RSV vaccine submitted globally for approval; Phase 3 melanoma combo trial with Merck initiated.

## SEC filing metadata
- accession: 0001682852-23-000025
- form_type: 8-K
- ticker: MRNA
- cik: 0001682852
- company_name: Moderna, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000025/0001682852-23-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000025/mrna-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001682852-23-000025
- JSON: https://secwatch.observer/filing/0001682852-23-000025.json
- Plain text: https://secwatch.observer/filing/0001682852-23-000025.txt

## Key facts
- Earnings Releases
  Moderna, Inc. reported the second quarter of 2023 results: revenue $344 million, net income net loss of $1.4 billion, EPS loss per share of $3.62. Guidance reaffirmed.
  - Period: the second quarter of 2023
  - Revenue: $344 million
  - Net income: net loss of $1.4 billion
  - EPS: loss per share of $3.62
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue for the second quarter of 2023 was $344 million, compared to $4.7 billion in the same period in 2022, mainly due to a decrease in sales of the Company’s COVID-19 vaccine.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682852/000168285223000025/0001682852-23-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.